PAVM
$10.39
PAVmed Inc.
Recent News
PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
PAVmed Inc (PAVM) reports significant strides in debt restructuring, strategic partnerships, and technology innovation, despite facing ongoing financial challenges.
PAVmed (PAVM) Upgraded to Strong Buy: Here's Why
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PAVmed plans to license Duke’s oesophageal imaging technology
A PAVmed subsidiary seeks to obtain exclusive worldwide licensing rights for Duke University’s a/LCI + OCT technology.
PAVmed subsidiary Veris Health partners with Ohio State University cancer center
PAVmed’s (PAVM) majority-owned digital health subsidiary Veris Health has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, or OSUCCC – James, a National Cancer Institute-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Ve
PAVmed Inc (PAVM) Q1 2025 Earnings Call Highlights: Strategic Expansion and Financial Fortification
PAVmed Inc (PAVM) strengthens its financial position and explores new opportunities in biopharma amidst ongoing challenges.